rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

MaxCyte, Inc.

MXCT · Nasdaq

Health CareLife-science toolsJust started movingSynthetic Biology / TechBio

MXCT stood above a rising 150-day average in 6 of the last 52 weekly readings, including each of the last 1 week. It is 20.2% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
1 in a row
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$17K
Officials’ trades on record
0
Institutions holding
118 (-4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 6 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$154K$0$456KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1
WhoDidSharesTraded
Douglas J. SwirskyCHIEF FINANCIAL OFFICERsold10,142at $0.81517 Mar 2026filed 19 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders118-4 on the quarter
New · exited28 · 33
Reported value$77.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Capricorn Fund Managers Ltdunchanged · filed 24 Jul 20268,200,000$10.1M00.0%
Vitruvian Partners LLPunchanged · filed 10 Aug 20265,043,356$6.2M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20264,031,284$5.0M+49,468+1.2%
MORGAN STANLEYadded · filed 13 Aug 20263,694,049$4.5M+5,918+0.2%
Mudita Advisors LLPunchanged · filed 13 Aug 20263,370,689$4.1M00.0%
BlackRock, Inc.reduced · filed 7 Aug 20263,060,960$3.8M-5,737,513−65.2%
Brooklands Fund Management Ltdadded · filed 11 Aug 20262,848,083$3.7M+658,063+30.0%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.unchanged · filed 13 Aug 20262,773,554$3.4M00.0%
CADIAN CAPITAL MANAGEMENT, LPadded · filed 14 Aug 20262,201,166$2.7M+478,224+27.8%
Peapod Lane Capital LLCadded · filed 27 Jul 20262,125,752$2.6M+793,559+59.6%
31 Mar 2023 – 30 Jun 2026
88105121Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Cynthia Collins Company insiderDirector · last 17 Jun 20260 · 0
John Joseph Johnston Company insiderDirector · last 17 Jun 20260 · 21
Patrick J. Balthrop Company insiderDirector · last 17 Jun 20260 · 0
Rekha Hemrajani Company insiderDirector · last 17 Jun 20260 · 1
Richard Douglas Company insiderDirector · last 17 Jun 20263 · 0
Stanley C. Erck Company insiderDirector · last 17 Jun 20261 · 5
William W. Brooke Company insiderDirector · last 17 Jun 20261 · 0
Yasir B. Al-Wakeel Company insiderDirector · last 17 Jun 20260 · 0
Parmeet Ahuja Company insiderChief Financial Officer · last 15 Apr 20260 · 0
Maher Masoud Company insiderPresident and CEO · last 27 Mar 20263 · 3
Douglas J. Swirsky Company insiderCHIEF FINANCIAL OFFICER · last 17 Mar 20261 · 2
Ali Soleymannezhad Company insiderChief Commercial Officer · last 18 Mar 20250 · 1

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202581.2%
Operating profit marginFY 2025 · to 31 Dec 2025-157%
Free cash flow marginFY 2025 · to 31 Dec 2025-110%
Return on capital employedFY 2025 · to 31 Dec 2025-27.6%
Research spendFY 2025 · to 31 Dec 202563.1%
Share count trendFY 2025 · to 17 Mar 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$20.1M
Free cash flowFY 2025 · to 31 Dec 2025−$36.2M

Analyst forecasts

No analyst forecasts yet.